Elevated intrinsic cancer stem cell population in human papillomavirus-associated head and neck squamous cell carcinoma

Cancer

Volumn 120, Issue 7, 2014, Pages 992-1001

  Zhang, Manchao ^a,b   Kumar, Bhavna ^a,b   Piao, Longzhu ^a,b   Xie, Xiujie ^a,b   Schmitt, Alessandra ^a   Arradaza, Nicole ^c   Cippola, Michael ^a,b   Old, Matthew ^a,b   Agrawal, Amit ^a,b   Ozer, Enver ^a,b   Schuller, David E ^a,b   Teknos, Theodoros N ^a,b   Pan, Quintin ^a,b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

ALDH1; cancer stem cells; cancer initiating cells; head and neck cancer; human papillomavirus; prognostic biomarker

Indexed keywords

ALDEHYDE DEHYDROGENASE; PROTEIN P53;

ADULT; ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER STEM CELL; CELL POPULATION; CONTROLLED STUDY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OROPHARYNX CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; SCID MOUSE; TISSUE MICROARRAY; XENOTRANSPLANTATION;

ALDH1; CANCER STEM CELLS; CANCER-INITIATING CELLS; HEAD AND NECK CANCER; HUMAN PAPILLOMAVIRUS; PROGNOSTIC BIOMARKER;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS;

EID: 84899448058     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28538     Document Type: Article

References (40)

1. Kamangar F, Dores GM, Anderson WF,. Patterns of cancer incidence, mortality, and prevalence across 5 continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24: 2137-2150.
2. Kreimer AR, Clifford GM, Boyle P, Franceschi S,. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14: 467-475.
3. Licitra L, Rossini C, Bossi P, Locati LD,. Advances in the changing patterns of aetiology of head and neck cancers. Curr Opin Otolaryngol Head Neck Surg. 2006; 14: 95-99.
4. Shiboski CH, Schmidt BL, Jordan RC,. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer. 2005; 103: 1843-1849.
5. Sturgis EM, Cinciripini PM,. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer. 2007; 110: 1429-1435.
6. Hammarstedt L, Lindquist D, Dahlstrand H, et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer. 2006; 119: 2620-2623.
7. Phillips TM, McBride WH, Pajonk F,. The response of CD24 (-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006; 98: 1777-1785.
8. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008; 100: 672-679.
9. Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009; 458: 780-783.
10. Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009; 106: 13820-13825.
11. Lagadec C, Vlashi E, Della Donna L, et al. Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment [serial online]. Breast Cancer Res. 2010; 12: R13.
12. Xie X, Piao L, Bullock BN, et al. Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma [published online ahead of print March 11, 2013 ]. Oncogene.
13. Clay MR, Tabor M, Owen JH, et al. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck. 2010; 32: 1195-1201.
14. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1: 555-567.
15. Huang EH, Hynes MJ, Zhang T, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009; 69: 3382-3389.
16. Jiang F, Qiu Q, Khanna A, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 2009; 7: 330-338.
17. Chen YC, Chen YW, Hsu HS, et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun. 2009; 385: 307-313.
18. Yu F, Yao H, Zhu P, et al. Let-7 regulates self-renewal and tumorigenicity of breast cancer cells. Cell. 2007; 131: 1109-1123.
19. Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006; 66: 6063-6071.
20. Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003; 17: 1253-1270.
21. Fichtner I, Rolff J, Soong R, et al. Establishment of patient-derived nonsmall cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 2008; 14: 6456-6468.
22. Reyal F, Guyader C, Decraene C, et al. Molecular profiling of patient-derived breast cancer xenografts [serial online]. Breast Cancer Res. 2012; 14: R11.
23. Tanei T, Morimoto K, Shimazu K, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 2009; 15: 4234-4241.
24. Deng S, Yang X, Lassus H, et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers [serial online]. PLoS One. 2010; 5: e10277.
25. Hong H, Takahashi K, Ichisaka T, et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature. 2009; 460: 1132-1135.
26. Kawamura T, Suzuki J, Wang YV, et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature. 2009; 460: 1140-1144.
27. Utikal J, Polo JM, Stadtfeld M, et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature. 2009; 460: 1145-1148.
28. Cicalese A, Bonizzi G, Pasi CE, et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell. 2009; 138: 1083-1095.
29. Xu J, Muller S, Nannapaneni S, et al. Comparison of quantum dot technology with conventional immunohistochemistry in examining aldehyde dehydrogenase 1A1 as a potential biomarker for lymph node metastasis of head and neck cancer. Eur J Cancer. 2012; 48: 1682-1691.
30. Koukourakis MI, Giatromanolaki A, Tsakmaki V, Danielidis V, Sivridis E,. Cancer stem cell phenotype relates to radio-chemotherapy outcome in locally advanced squamous cell head-neck cancer. Br J Cancer. 2012; 106: 846-853.
31. Neumeister V, Agarwal S, Bordeaux J, Camp RL, Rimm DL,. In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol. 2010; 176: 2131-2138.
32. Charafe-Jauffret E, Ginestier C, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 2010; 16: 45-55.
33. Dimou A, Neumeister V, Agarwal S, Anagnostou V, Syrigos K, Rimm DL,. Measurement of aldehyde dehydrogenase 1 expression defines a group with better prognosis in patients with nonsmall cell lung cancer. Am J Pathol. 2012; 181: 1436-1442.
34. Resetkova E, Reis-Filho JS, Jain RK, et al. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat. 2009; 123: 97-108.
35. Zhou JH, Hanna EY, Roberts D, Weber RS, Bell D,. ALDH1 immunohistochemical expression and its significance in salivary adenoid cystic carcinoma. Head Neck. 2013; 35: 575-578.
36. Liu S, Ginestier C, Ou SJ, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 2011; 71: 614-624.
37. Lim YC, Oh SY, Cha YY, Kim SH, Jin X, Kim H,. Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas. Oral Oncol. 2011; 47: 83-91.
38. Sun S, Wang Z,. Head neck squamous cell carcinoma c-Met(+) cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis. Int J Cancer. 2011; 129: 2337-2348.
39. Chikamatsu K, Ishii H, Takahashi G, et al. Resistance to apoptosis-inducing stimuli in CD44+ head and neck squamous cell carcinoma cells. Head Neck. 2012; 34: 336-343.
40. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363: 24-35.